Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis

References

• Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov. 2020 Oct;19(10):711–736. doi: 10.1038/s41573-020-0076-6
   PubMed Web of Science ®Google Scholar
• Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci USA. 2011 Feb 22;108(8):3406–3411. doi: 10.1073/pnas.1013715108
   PubMed Web of Science ®Google Scholar
• Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008 Aug 1;26(22):3785–3790. doi: 10.1200/JCO.2008.16.0812
   PubMed Web of Science ®Google Scholar
• Pavlidis N, Rassy E, Vermorken JB, et al. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021 Dec;75:102045. doi: 10.1016/j.canep.2021.102045
   PubMed Web of Science ®Google Scholar
• Miller RE, Leary A, Scott CL, et al. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Ann Oncol. 2020 Dec;31(12):1606–1622. doi: 10.1016/j.annonc.2020.08.2102
   PubMed Web of Science ®Google Scholar
• Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncol. 2021 Dec;22(12):1721–1731. doi: 10.1016/S1470-2045(21)00531-3
   PubMed Web of Science ®Google Scholar
• Nguyen L, J WMM, Van Hoeck A, et al. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020 Nov 4;11(1):5584. doi: 10.1038/s41467-020-19406-4
   PubMed Web of Science ®Google Scholar
• Boussios S, Rassy E, Shah S, et al. Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology. Expert Opin Ther Targets. 2021 May;25(5):329–333. doi: 10.1080/14728222.2021.1951226
   PubMed Web of Science ®Google Scholar
• Cai Z, Liu C, Chang C, et al. Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis. Pharmacol Res. 2021 Oct;172:105808. doi: 10.1016/j.phrs.2021.105808
   PubMed Web of Science ®Google Scholar
• Markham A. Pamiparib: First Approval. Drugs. 2021 Jul;81(11):1343–1348. doi: 10.1007/s40265-021-01552-8
   PubMed Web of Science ®Google Scholar
• Friedlander M, Matulonis U, Gourley C, et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018 Oct;119(9):1075–1085. doi: 10.1038/s41416-018-0271-y
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2017 Oct 28;390(10106):1949–1961. doi: 10.1016/S0140-6736(17)32440-6
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 Dec 1;375(22):2154–2164. doi: 10.1056/NEJMoa1611310
   PubMed Web of Science ®Google Scholar
• Li N, Zhang Y, Wang J, et al. Fluzoparib maintenance therapy in patients with platinum-sensitive, recurrent ovarian carcinoma (fzocus-2): a Multicenter, Randomized, Double-Blind, Placebo-Controlled, phase III trial. J Clin Oncol. 2022 Aug 1;40(22):2436–2446. doi: 10.1200/JCO.21.01511
   PubMed Web of Science ®Google Scholar
• Tew WP, Lacchetti C, Kohn EC. Poly(hypencapswithspaceretaincoll1ibose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022 Nov 20;40(33):3878–3881. doi: 10.1200/JCO.22.01934
   PubMed Web of Science ®Google Scholar
• Tung NM, Zakalik D, Somerfield MR. Adjuvant PARP inhibitors in patients with high-risk early-stage HER2-negative breast cancer and germline BRCA mutations: ASCO hereditary breast cancer guideline rapid recommendation update. J Clin Oncol. 2021 Sep 10;39(26):2959–2961. doi: 10.1200/JCO.21.01532
   PubMed Web of Science ®Google Scholar
• Wang C, Li J. Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials. J Clin Pharm Ther. 2021 Jun;46(3):571–584. doi: 10.1111/jcpt.13349
   PubMed Web of Science ®Google Scholar
• Yan YD, Zhao Y, Zhang C, et al. Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system. EClinicalMedicine. 2022 Aug;50:101535. doi: 10.1016/j.eclinm.2022.101535
   PubMedGoogle Scholar
• Shu Y, Ding Y, He X, et al. Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database. Cancer Med. 2022 Jul 24;12(3):3365–3375. doi: 10.1002/cam4.5062
   PubMed Web of Science ®Google Scholar
• Ma Z, Sun X, Zhao Z, et al. Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database. Gynecol Oncol. 2021 Aug;162(2):496–505. doi: 10.1016/j.ygyno.2021.05.012
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Internal Med. 2015 Jun 2;162(11):777–784. doi: 10.7326/M14-2385
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. [2011 Oct 18];343(oct18 2):d5928. doi: 10.1136/bmj.d5928
   PubMedGoogle Scholar
• Zhang P, Wei S, Zhai K, et al. Efficacy of left ventricular unloading strategies during venoarterial extracorporeal membrane oxygenation in patients with cardiogenic shock: a protocol for a systematic review and Bayesian network meta-analysis. BMJ Open. 2021 Oct 19;11(10):e047046. doi: 10.1136/bmjopen-2020-047046
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. [1997 Sep 13];315(7109):629–634. doi: 10.1136/bmj.315.7109.629
   PubMedGoogle Scholar
• Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):519–523. doi: 10.1002/pds.1001
   PubMed Web of Science ®Google Scholar
• Chen C, Wu B, Zhang C, et al. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol. 2021 Jun;95:107498. doi: 10.1016/j.intimp.2021.107498
   PubMed Web of Science ®Google Scholar
• Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382–1392. doi: 10.1056/NEJMoa1105535
   PubMed Web of Science ®Google Scholar
• Bang YJ, Im SA, Lee KW, et al. Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J Clin Oncol. 2015 Nov 20;33(33):3858–3865. doi: 10.1200/JCO.2014.60.0320
   PubMed Web of Science ®Google Scholar
• Bang YJ, Xu RH, Chin K, et al. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1637–1651. doi: 10.1016/S1470-2045(17)30682-4
   PubMed Web of Science ®Google Scholar
• Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018 Jul;19(7):975–986. doi: 10.1016/S1470-2045(18)30365-6
   PubMed Web of Science ®Google Scholar
• González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019 Dec 19;381(25):2391–2402. doi: 10.1056/NEJMoa1910962
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019 Dec 19;381(25):2416–2428. doi: 10.1056/NEJMoa1911361
   PubMed Web of Science ®Google Scholar
• Garcia-Campelo R, Arrieta O, Massuti B, et al. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung Cancer. 2020 Dec;150:62–69. doi: 10.1016/j.lungcan.2020.09.018
   PubMed Web of Science ®Google Scholar
• Ai X, Pan Y, Shi J, et al. Efficacy and safety of niraparib as maintenance treatment in patients with extensive-stage SCLC after first-line chemotherapy: a randomized, double-blind, phase 3 study. J Thorac Oncol. 2021 Aug;16(8):1403–1414. doi: 10.1016/j.jtho.2021.04.001
   PubMed Web of Science ®Google Scholar
• Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 May;22(5):620–631. doi: 10.1016/S1470-2045(21)00073-5
   PubMed Web of Science ®Google Scholar
• Wu XH, Zhu JQ, Yin RT, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial(☆). Ann Oncol. 2021 Apr;32(4):512–521. doi: 10.1016/j.annonc.2020.12.018
   PubMed Web of Science ®Google Scholar
• Fennell DA, Porter C, Lester J, et al. Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine. 2022 Oct;52:101595. doi: 10.1016/j.eclinm.2022.101595
   PubMedGoogle Scholar
• Geyer CE Jr., Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 Dec;33(12):1250–1268. doi: 10.1016/j.annonc.2022.09.159
   PubMed Web of Science ®Google Scholar
• Kindler HL, Hammel P, Reni M, et al. Overall survival results from the POLO trial: A phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022 Dec 1;40(34):3929–3939. doi: 10.1200/JCO.21.01604
   PubMed Web of Science ®Google Scholar
• Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022 Dec 1;40(34):3952–3964. doi: 10.1200/JCO.22.01003
   PubMed Web of Science ®Google Scholar
• Woll P, Gaunt P, Danson S, et al. Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial. Lung Cancer. 2022 Sep;171:26–33. doi: 10.1016/j.lungcan.2022.07.007
   PubMed Web of Science ®Google Scholar
• Crabb SJ, Hussain S, Soulis E, et al. A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-Ribose polymerase inhibition with rucaparib following chemotherapy for metastatic urothelial carcinoma. J Clin Oncol. 2023 Jan 1;41(1):54–64. doi: 10.1200/JCO.22.00405
   PubMed Web of Science ®Google Scholar
• DiSilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol. 2023 Jan 20;41(3):609–617. doi: 10.1200/JCO.22.01549
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Park SH, Kozlov V, et al. Durvalumab plus olaparib in previously untreated, platinum-Ineligible Patients with Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II trial (BAYOU). J Clin Oncol. 2023 Jan 1;41(1):43–53. doi: 10.1200/JCO.22.00205
   PubMed Web of Science ®Google Scholar
• Vignani F, Tambaro R, De Giorgi U, et al. Addition of niraparib to best supportive care as maintenance treatment in patients with advanced urothelial carcinoma whose disease did not progress after first-line platinum-based chemotherapy: the meet-URO12 randomized phase 2 trial. Eur Urol. 2023 Jan;83(1):82–89. doi: 10.1016/j.eururo.2022.09.025
   PubMed Web of Science ®Google Scholar
• Westin SN, Moore K, Chon HS, et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial. J Clin Oncol. 2024 Jan 20;42(3):283–299. doi: 10.1200/JCO.23.02132
   PubMed Web of Science ®Google Scholar
• Chi KN, Sandhu S, Smith MR, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023 Sep;34(9):772–782. doi: 10.1016/j.annonc.2023.06.009
   PubMed Web of Science ®Google Scholar
• Li N, Zhu J, Yin R, et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2023 Sep 1;9(9):1230–1237. doi: 10.1001/jamaoncol.2023.2283
   PubMed Web of Science ®Google Scholar
• Saad F, Clarke NW, Oya M, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023 Oct;24(10):1094–1108. doi: 10.1016/S1470-2045(23)00382-0
   PubMed Web of Science ®Google Scholar
• Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2023 Jul 22;402(10398):291–303. doi: 10.1016/S0140-6736(23)01055-3
   PubMed Web of Science ®Google Scholar
• Wang H, Wu M, Liu H, et al. Comparison of the efficacy and safety of PARP inhibitors as a monotherapy for platinum-sensitive recurrent ovarian cancer: a network meta-analysis. Front Oncol. 2021;11:785102. doi: 10.3389/fonc.2021.785102
   PubMed Web of Science ®Google Scholar
• Luo J, Ou S, Wei H, et al. Comparative efficacy and safety of poly (ADP-Ribose) polymerase inhibitors in patients with ovarian cancer: a systematic review and network meta-analysis. Front Oncol. 2022;12:815265. doi: 10.3389/fonc.2022.815265
   PubMed Web of Science ®Google Scholar
• Revythis A, Limbu A, Mikropoulos C, et al. Recent insights into parp and immuno-checkpoint inhibitors in epithelial ovarian cancer. Int J Environ Res Public Health. 2022 Jul 14;19(14):8577. doi: 10.3390/ijerph19148577
   PubMed Web of Science ®Google Scholar
• Bao S, Yue Y, Hua Y, et al. Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials. Ann Translat Med. 2021 Aug;9(15):1229. doi: 10.21037/atm-21-1883
   PubMed Web of Science ®Google Scholar
• Valabrega G, Scotto G, Tuninetti V, et al. Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy. Int J Mol Sci. 2021 Apr 19;22(8):4203. doi: 10.3390/ijms22084203
   PubMed Web of Science ®Google Scholar
• Thorsell AG, Ekblad T, Karlberg T, et al. Structural basis for potency and promiscuity in poly(ADP-ribose) Polymerase (PARP) and tankyrase inhibitors. J Med Chem. 2017 Feb 23;60(4):1262–1271. doi: 10.1021/acs.jmedchem.6b00990
   PubMed Web of Science ®Google Scholar
• Sandhu D, Antolin AA, Cox AR, et al. Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale. Br J Clin Pharmacol. 2022 Feb;88(2):742–752. doi: 10.1111/bcp.15015
   PubMed Web of Science ®Google Scholar
• Illuzzi G, Staniszewska AD, Gill SJ, et al. Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724–4736. doi: 10.1158/1078-0432.CCR-22-0301
   PubMed Web of Science ®Google Scholar
• Diaz D, Ford KA, Hartley DP, et al. Pharmacokinetic drivers of toxicity for basic molecules: strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor. Toxicol Appl Pharmacol. 2013 Jan 1;266(1):86–94. doi: 10.1016/j.taap.2012.10.026
   PubMed Web of Science ®Google Scholar
• LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019 Jan;20(1):e15–e28. doi: 10.1016/S1470-2045(18)30786-1
   PubMed Web of Science ®Google Scholar
• Society Of O, Gynecology Of Zhejiang Medical A, Society Of Urology Of Zhejiang Medical A. Guidance on the management of adverse reactions induced by poly(ADP-ribose) polymerase inhibitors. Zhejiang da xue xue bao Yi xue ban = J Zhejiang Uni Med sci. 2023 Feb 25;51(6):765–774. doi: 10.3724/zdxbyxb-2022-0284
   Google Scholar